Invivyd (NASDAQ:IVVD – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at D. Boral Capital in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $9.00 price objective on the stock.
IVVD has been the topic of a number of other reports. HC Wainwright dropped their price target on shares of Invivyd from $15.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, November 20th. EF Hutton Acquisition Co. I upgraded Invivyd to a “strong-buy” rating in a research report on Wednesday, October 30th. Finally, Morgan Stanley dropped their price objective on Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a report on Wednesday, November 20th. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Invivyd has a consensus rating of “Buy” and a consensus target price of $7.89.
Check Out Our Latest Research Report on Invivyd
Invivyd Stock Performance
Insiders Place Their Bets
In other Invivyd news, Director Terrance Mcguire sold 119,805 shares of the business’s stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $0.42, for a total value of $50,318.10. Following the completion of the transaction, the director now owns 3,568,274 shares of the company’s stock, valued at $1,498,675.08. The trade was a 3.25 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 816,466 shares of company stock worth $423,214 in the last ninety days. 17.90% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in IVVD. Barclays PLC raised its holdings in shares of Invivyd by 179.6% during the 3rd quarter. Barclays PLC now owns 117,973 shares of the company’s stock valued at $120,000 after buying an additional 75,780 shares in the last quarter. State Street Corp lifted its holdings in shares of Invivyd by 3.7% in the 3rd quarter. State Street Corp now owns 1,018,640 shares of the company’s stock worth $1,039,000 after acquiring an additional 35,904 shares during the last quarter. Proficio Capital Partners LLC purchased a new stake in shares of Invivyd in the 3rd quarter valued at $27,000. Cubist Systematic Strategies LLC grew its holdings in shares of Invivyd by 66.1% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock valued at $148,000 after purchasing an additional 53,499 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC purchased a new position in Invivyd in the 2nd quarter worth $115,000. Institutional investors own 70.36% of the company’s stock.
About Invivyd
Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.
Read More
- Five stocks we like better than Invivyd
- 3 Healthcare Dividend Stocks to Buy
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- Comparing and Trading High PE Ratio Stocks
- What Does the Future Hold for Eli Lilly?
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for Invivyd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivyd and related companies with MarketBeat.com's FREE daily email newsletter.